Press Releases

Date Title and Summary Additional Formats
Toggle Summary Amicus Therapeutics Completes Enrollment in ESSENCE Phase 3 Epidermolysis Bullosa Clinical Study
Target Exceeded with More than 160 Patients Enrolled Top-Line Data on Track for 3Q17 CRANBURY, N.J. , April 03, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, has completed enrollment in the
View HTML
Toggle Summary Amicus Therapeutics Launches Galafold™ (Migalastat) for Treatment of Fabry Disease in Italy
Ministry of Health Publishes Final Guidance Covering Reimbursement of Galafold for Fabry Disease
View HTML
Toggle Summary Amicus Therapeutics to Present at Upcoming Investor Conferences
CRANBURY, N.J. , March 02, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that management will present at two upcoming investor conferences.
View HTML
Toggle Summary Amicus Therapeutics Announces Full-Year 2016 Financial Results and Corporate Updates
Growing Momentum for EU Galafold (Migalastat) Launch for Fabry Disease Tracking Toward 300 Patients by Year-End 2017  Target Enrollment Achieved in Phase 1/2 Pompe Study - Additional Data Expected in 2Q17 and 3Q17 Phase 3 EB Program Remains on Track for Topline Data in Mid-2017 CRANBURY, N.J.
View HTML
Toggle Summary Amicus Therapeutics Launches Galafold™ (Migalastat) for Treatment of Fabry Disease in the United Kingdom
National Institute for Health and Care Excellence (NICE) Publishes Final Guidance Covering Reimbursement of Galafold for Fabry Disease CRANBURY, N.J. , Feb. 27, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of rare and orphan diseases,
View HTML
Toggle Summary Amicus Therapeutics to Announce Full-Year 2016 Financial Results and Corporate Updates on March 1, 2017
CRANBURY, N.J. , Feb. 22, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced a conference call and live audio webcast on Wednesday, March 1, 2017 at 8:30 a.m.
View HTML
Toggle Summary Amicus Therapeutics Presents Additional Positive Preliminary Phase 1/2 Data at WORLDSymposium™ 2017
Biomarkers of Muscle Damage (AST, ALT and CK) Demonstrate Improving Trends in Majority of Patients Biomarker of Key Disease Substrate (Hex4) Demonstrates Improving Trend in All Patients Safety Data Continue to Show No Infusion-Associated Reactions Following 150+ Infusions CRANBURY, N.J.
View HTML
Toggle Summary Amicus Therapeutics Presents Important New Scientific Findings and Preclinical Data for Pompe Program at WORLDSymposium™ 2017
Scientific Findings Reveal that Cellular Damage Alters Trafficking for Key Proteins Involved in Muscle Membrane Integrity and Muscle Repair Preclinical Studies Demonstrate Reversal of Cellular Damage and Significant Improvements in Muscle Strength in GAA Knock-out Mice After Treatment with Amicus
View HTML
Toggle Summary Amicus Therapeutics Highlights New Fabry Program Data at WORLDSymposium™ 2017
New Phase 3 Retrospective Analysis Shows Correlation between Reduction in Disease Substrate (Kidney Interstitial Capillary GL-3) and Improved Diarrhea in Fabry Patients with Amenable Mutations treated with Migalastat Supportive Study for Japanese New Drug Application (J-NDA) Demonstrates Migalastat
View HTML
Toggle Summary Amicus Therapeutics to Present at the Leerink Partners 6th Annual Global Healthcare Conference
CRANBURY, N.J. , Feb. 06, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that Chip Baird , Chief Financial Officer, will participate in a corporate overview and fireside chat at
View HTML